Antibody-drug conjugates in prostate cancer Miscellaneous
| Author: | Danila, D. C. |
| Title: | Antibody-drug conjugates in prostate cancer |
| Keywords: | leukemia; unclassified drug; gene mutation; note; gene; metastasis; nephrotoxicity; bladder cancer; prostate cancer; gastrointestinal toxicity; prostate specific membrane antigen; epitope; membrane protein; lymphoma; xerostomia; autoantibody; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; olaparib; gemtuzumab ozogamicin; programmed death 1 ligand 1; abiraterone; inotuzumab ozogamicin; trastuzumab emtansine; cabazitaxel; gamma glutamyl hydrolase; brentuximab vedotin; enzalutamide; rucaparib; radium chloride ra 223; pembrolizumab; apalutamide; antibody drug conjugate; darolutamide; enfortumab vedotin; sacituzumab govitecan; trastuzumab deruxtecan; six transmembrane epithelial antigen of the prostate; solute carrier family 44 member 4; solute carrier protein; trodelvy; tumor associated calcium signal transducer 2 |
| Journal Title: | Clinical Advances in Hematology & Oncology |
| Volume: | 18 |
| Issue: | 8 |
| ISSN: | 1543-0790 |
| Publisher: | Millennium Medical Publishing, Inc |
| Date Published: | 2020-08-01 |
| Start Page: | 447 |
| End Page: | 449 |
| Language: | English |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Note -- Export Date: 1 September 2020 -- Source: Scopus |
MSK Authors
-
154Danila